ABL Diagnostics wins court approval to take over TEXCELL activities

ABL Diagnostics has been designated by the Évry Commercial Court to acquire TEXCELL’s assets and operations, giving the French diagnostics group a stronger foothold in virology, biosafety and infectious-disease services at Genopole in Évry-Courcouronnes. The deal includes 29 employees, transferred contracts and planned investment as ABL Diagnostics expands its molecular diagnostics platform.

Why it matters: - The takeover expands ABL Diagnostics into adjacent life-science services with direct relevance to virology, biosafety and biological control. - The deal preserves activity and expertise at the Genopole site in Évry-Courcouronnes. - The acquisition adds complementary capabilities that can support ABL Diagnostics’ existing molecular diagnostics platforms and future R&D.

What happened: - ABL Diagnostics was designated by the Évry Commercial Court to take over TEXCELL’s assets and activities. - The decision follows ABL Diagnostics’ industrial plan to maintain operations, retain scientific know-how and build synergies with its current businesses. - The company said the acquisition is intended to support continuity on the Genopole site and align with its broader strategy in molecular diagnostics, virology and infectious diseases.

The details: - The transaction covers TEXCELL’s strategic assets and activities. - Transferred commercial contracts will continue under the acquisition structure. - The Genopole site in Évry-Courcouronnes will remain operational. - ABL Diagnostics will take on 29 employees, including 23 permanent staff and 6 apprentices. - The company will also assume acquired employee rights valued at €91,829.24, subject to adjustment. - TEXCELL’s legacy includes expertise in viral safety, biosafety, genomic analysis, immune monitoring and services for biotechnology and innovative therapies. - Publicly available information shows TEXCELL France generated about €5.4 million in 2024, down from €6.2 million in 2023 and €7.5 million in 2022. - The overall economic value of the project is about €2.9 million. - That total includes a €225,000 asset sale price, split between €165,000 for intangible assets and €60,000 for tangible assets. - The deal includes stock acquisition for €30,000 excluding tax. - It also includes reconstitution of security deposits of about €100,000. - ABL Diagnostics will take over equipment-related lease-finance contracts and future installments worth €531,792.74, subject to adjustment. - The plan includes €930,000 in industrial and technology investment. - ABL Diagnostics also expects a €1 million increase in working capital to support the acquired activities. - The acquisition is being funded from the group’s available financial resources. - The terms of the winning offer are contained in documents filed with the Évry Commercial Court.

Between the lines: - The deal deepens ABL Diagnostics’ scientific link to the Institut Pasteur ecosystem, following a recent HPV RNA-Seq genotyping project with Institut Pasteur de Paris. - TEXCELL’s origins in that ecosystem make the combination strategically coherent for a company building around virology and infectious-disease capabilities. - The acquired expertise in viral safety, biological control, cell culture, viral characterization and biosafety fits with ABL Diagnostics’ UltraGene, DeepChek® and Nadis® platforms. - The company plans to add about five more employees at the site, signaling an intent to scale the operation rather than simply absorb it. - The assets could feed future tools for biomedical research, biological quality control and molecular diagnostics. - Dr. Chalom Sayada said TEXCELL adds recognized scientific skills, qualified teams, an established international brand and complementary biological assets. - Sayada also said the company plans to invest in automation, infrastructure upgrades, team expansion and scientific development.

What's next: - ABL Diagnostics will communicate later on the integration of the acquired activities. - The company will also update the market on how the transaction fits into its 2026 roadmap and objectives, once legal and administrative steps are complete. - The press release notes the transaction includes forward-looking statements that remain subject to judicial outcomes and third-party approvals.